Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SAKAR HEALTHCARE ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SAKAR HEALTHCARE Mar-23 |
ADCOCK INGRAM Jun-14 |
SAKAR HEALTHCARE / ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 295 | 331 | - | |
Low | Rs | 112 | 238 | - | |
Sales per share (Unadj.) | Rs | 70.0 | 98.3 | - | |
Earnings per share (Unadj.) | Rs | 6.7 | -24.8 | - | |
Cash flow per share (Unadj.) | Rs | 14.6 | -20.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 91.0 | 77.2 | - | |
Shares outstanding (eoy) | m | 19.04 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.9 | 2.9 | 100.4% | |
Avg P/E ratio | x | 30.4 | -11.5 | -264.3% | |
P/CF ratio (eoy) | x | 14.0 | -13.9 | -100.7% | |
Price / Book Value ratio | x | 2.2 | 3.7 | 60.6% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 3,873 | 48,025 | 8.1% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 158 | 3,014 | 5.2% | |
Avg. sales/employee | Rs Th | 0 | 3,866.4 | - | |
Avg. wages/employee | Rs Th | 0 | 702.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -974.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,334 | 16,598 | 8.0% | |
Other income | Rs m | 47 | 116 | 40.2% | |
Total revenues | Rs m | 1,380 | 16,715 | 8.3% | |
Gross profit | Rs m | 333 | -2,876 | -11.6% | |
Depreciation | Rs m | 150 | 716 | 20.9% | |
Interest | Rs m | 60 | 450 | 13.3% | |
Profit before tax | Rs m | 170 | -3,926 | -4.3% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 42 | 245 | 17.3% | |
Profit after tax | Rs m | 128 | -4,182 | -3.1% | |
Gross profit margin | % | 24.9 | -17.3 | -143.9% | |
Effective tax rate | % | 24.9 | -6.2 | -398.7% | |
Net profit margin | % | 9.6 | -25.2 | -38.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 559 | 12,157 | 4.6% | |
Current liabilities | Rs m | 545 | 6,840 | 8.0% | |
Net working cap to sales | % | 1.1 | 32.0 | 3.3% | |
Current ratio | x | 1.0 | 1.8 | 57.7% | |
Inventory Days | Days | 29 | 111 | 26.6% | |
Debtors Days | Days | 604 | 124 | 487.5% | |
Net fixed assets | Rs m | 2,804 | 7,086 | 39.6% | |
Share capital | Rs m | 190 | 77 | 247.1% | |
Net worth | Rs m | 1,733 | 13,028 | 13.3% | |
Long term debt | Rs m | 982 | 4,578 | 21.5% | |
Total assets | Rs m | 3,363 | 24,611 | 13.7% | |
Interest coverage | x | 3.8 | -7.7 | -49.8% | |
Debt to equity ratio | x | 0.6 | 0.4 | 161.2% | |
Sales to assets ratio | x | 0.4 | 0.7 | 58.8% | |
Return on assets | % | 5.6 | -15.2 | -36.7% | |
Return on equity | % | 7.4 | -32.1 | -22.9% | |
Return on capital | % | 8.5 | -19.8 | -42.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 333 | 1,417 | 23.5% | |
From Investments | Rs m | -744 | -435 | 171.0% | |
From Financial Activity | Rs m | 411 | 4,155 | 9.9% | |
Net Cashflow | Rs m | 1 | 5,137 | 0.0% |
Compare SAKAR HEALTHCARE With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SAKAR HEALTHCARE With: ORCHID PHARMA J.B.CHEMICALS DECCAN HEALTH CARE LUPIN RPG LIFE SCIENCES
Indian share markets continued the momentum as the session progressed and ended on firm footing.